Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China

中国 医学 细胞疗法 遗传增强 政府(语言学) 公司治理 经济增长 业务 政治学 财务 生物 细胞 基因 遗传学 生物化学 语言学 哲学 经济 法学
作者
Xiaolei Li,Hanren Dai,Yao Wang,Zhiqiang Wu,Hua Wang,Wenbin Qian,Aibin Liang,Weidong Han
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:9 (12): e942-e954 被引量:12
标识
DOI:10.1016/s2352-3026(22)00331-3
摘要

Chimeric antigen receptor (CAR) T-cell therapy is an example of gene engineering-based cellular therapy, which combines immunotherapy, gene therapy, and cellular therapy. Historically, the second clinical trial of gene therapy for patients with haemophilia B was conducted by Chinese scientists in 1991, and China became the first country to approve a commercial gene therapy product in 2003. However, China almost lost its lead in this field, partly due to an early scarcity of clear and cohesive policies regarding cellular therapy. Cellular therapy is not only a novel medical practice but also a medicinal product. The increasing commercialisation of globally approved cell therapy products made the Chinese Government issue a series of relevant policies to promote the canonical development of cell therapy and its standardisation in China. Encouraged by flexible regulatory frameworks that have facilitated the development of cellular therapy since 2017, remarkable progress has been achieved, thereby putting China back at the forefront of the field worldwide. Some policies on cellular therapy launched by the Chinese government in 2019 have contributed to the growth of cellular therapy in China; however, the regulation, governance, and management of commercialised products remain challenging. This Series paper aims to provide an overview of the current regulatory reforms on clinical cellular therapy in China with a historical perspective. We also highlight several important contributors that could promote innovation and industrialisation of cellular therapy in China. Further efforts are needed to establish a legislative system with clear and cohesive policies for the increasing use of cellular therapy in China, enabling a more prescriptive, diligent, and informed process.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苹果思天发布了新的文献求助10
1秒前
SciGPT的应助被波罗蜜采纳,获得10
1秒前
Yan发布了新的文献求助100
2秒前
syvshc的应助被时平谊采纳,获得10
2秒前
SciGPT的应助被徐XU采纳,获得10
3秒前
科目三的应助被ren采纳,获得10
4秒前
有机者发布了新的文献求助10
4秒前
在水一方的应助被大知闲闲采纳,获得10
5秒前
嗷嗷发布了新的文献求助10
6秒前
wy完成签到 ,获得积分10
7秒前
表弟慢热手的应助被时平谊采纳,获得30
8秒前
9秒前
善良此刻完成签到 ,获得积分10
9秒前
9秒前
大方的千雁完成签到,获得积分10
9秒前
hou完成签到,获得积分10
10秒前
10秒前
直率的飞雪完成签到,获得积分10
10秒前
11秒前
12秒前
十一完成签到,获得积分10
13秒前
表弟慢热手的应助被玊尔玉采纳,获得10
14秒前
一号小玩家完成签到,获得积分10
14秒前
dde发布了新的文献求助10
15秒前
wwww发布了新的文献求助10
15秒前
16秒前
专注小猫咪完成签到 ,获得积分10
16秒前
ren发布了新的文献求助10
16秒前
keyantong完成签到,获得积分10
16秒前
天成发布了新的文献求助10
16秒前
Maestro_S的应助被oblivion采纳,获得10
17秒前
18秒前
18秒前
18秒前
18秒前
18秒前
18秒前
19秒前
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582